Brigatinib
Brigatinib | CAS NO: 1197953-54-0 , Brigatinib is used to treat a certain type of non-small cell lung cancer (NSCLC) that has spread to other parts of the bodys. Brigatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply.
We are the Synchemia Research Chemical specializes in manufacturing and supplying of Brigatinib impurities that meet specific pharmacopeial standards (EP/BP/USP/IP) as well as process-related impurities. Brigatinib is used to treat a certain type of non-small cell lung cancer (NSCLC) that has spread to other parts of the bodys. Brigatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. Buy Reliable and High-Purity Brigatinib Impurities, Delivered by Synchemia Research Chemicals.
Pharmaceutical Reference Standards
| CAT No | SRC-B30251 |
| CAS No | 1197953-54-0 |
| Mol.F. | C29H39ClN7O2P |
| Mol.Wt. | 584.1g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-B30252 |
| CAS No | 1197960-18-1 |
| Mol.F. | C30H41ClN7O2P |
| Mol.Wt. | 598.1g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-B30253 |
| CAS No | 1197961-02-6 |
| Mol.F. | C30H41ClN7O2P |
| Mol.Wt. | 598.1g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-B30254 |
| CAS No | 1197958-75-0 |
| Mol.F. | C28H37ClN7O2P |
| Mol.Wt. | 570.1g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-B30255 |
| CAS No | NA |
| Mol.F. | C38H55ClN10O2 |
| Mol.Wt. | 719.4g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-B30256 |
| CAS No | 1197959-30-0 |
| Mol.F. | C24H29ClN5O3P |
| Mol.Wt. | 502g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-B30257 |
| CAS No | 1259274-28-6 |
| Mol.F. | C21H28Cl2N6O |
| Mol.Wt. | 451.4g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
Let’s advance your research together.
Partner with us for specialized chemical materials and synthesis services that enable pharmaceutical innovation.